A research team has uncovered new insights into the molecular mechanisms of ADAR1, a protein that regulates ribonucleic acid (RNA) induced immune responses. Their findings could open new pathways for treating autoimmune diseases and enhancing cancer immunotherapy.
Tag: Cancer Immunotherapy
Anti-vascular endothelial growth factor treatment potentiates immune checkpoint blockade through a BAFF- and IL-12-dependent reprogramming of the TME
VEGF blockade is known to enhance immune checkpoint blockade (ICB) efficacy, but its precise immunological mechanism remains undefined. Benmebarek et al. reveal that VEGF inhibition drives BAFF- and IL-12-dependent Treg reprogramming, promoting a fragile, Th1-like state that amplifies anti-tumor immunity in cholangiocarcinoma.
New immunotherapy strategy for enhancing melanoma treatment
Researchers have found a new way to boost cancer immunotherapy by targeting a protein called macrophage receptor with collagenous structure, or MARCO. Their study shows that blocking MARCO in combination with a type of immunotherapy known as anti-CTLA4 therapy, significantly enhances tumor regression in melanoma, the deadliest form of skin cancer.
Type I IFNs contribute to upregulation of PD-L1 during Chlamydia trachomatis infection
Infection and Immunity, Ahead of Print.
Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols
Immunotherapy of cancer is now an essential pillar of treatment for patients with many individual tumor types. Novel immune targets and technical advances are driving a rapid exploration of new treatment strategies incorporating immune agents in cancer clinical practice. Immunotherapies perturb a complex system of interactions among genomically unstable tumor cells, diverse cells within the… Continue reading Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols
PD-1IR2 promotes tumor evasion via deregulating CD8+ T cell function
Background The programmed cell death 1 (PD-1) is an immune checkpoint that mediates immune evasion of tumors. Alternative splicing (AS) such as intron retention (IR) plays a crucial role in the immune-related gene processing and its function. However, it is not clear whether PDCD1 encoding PD-1 exists as an IR splicing isoform and what underlying… Continue reading PD-1IR2 promotes tumor evasion via deregulating CD8+ T cell function
Prognostic and predictive values of a multimodal nomogram incorporating tumor and peritumor morphology with immune status in resectable lung adenocarcinoma
Background Current prognostic and predictive biomarkers for lung adenocarcinoma (LUAD) predominantly rely on unimodal approaches, limiting their characterization ability. There is an urgent need for a comprehensive and accurate biomarker to guide individualized adjuvant therapy decisions. Methods In this retrospective study, data from patients with resectable LUAD (stage I–III) were collected from two hospitals and… Continue reading Prognostic and predictive values of a multimodal nomogram incorporating tumor and peritumor morphology with immune status in resectable lung adenocarcinoma
Cell-intrinsic PD-L1 signaling drives immunosuppression by myeloid-derived suppressor cells through IL-6/Jak/Stat3 in PD-L1-high lung cancer
Background Some patients with non-small-cell lung cancer (NSCLC) benefit from immune checkpoint inhibitors (ICIs) despite programmed death-ligand 1 (PD-L1) expression. To address the mechanism of ICI resistance in PD-L1-positive NSCLC, we investigated the role of tumor-cell-intrinsic function of PD-L1 in interleukin (IL)-6-mediated immunosuppression. Methods Cohorts of NSCLC patients treated with ICI and public datasets were… Continue reading Cell-intrinsic PD-L1 signaling drives immunosuppression by myeloid-derived suppressor cells through IL-6/Jak/Stat3 in PD-L1-high lung cancer
Identification of a conserved subset of cold tumors responsive to immune checkpoint blockade
Background The efficacy of immune checkpoint blockade (ICB) depends on restoring immune recognition of cancer cells that have evaded immune surveillance. Transforming growth factor-beta (TGFβ) is associated with immune-poor, so-called cold tumors whereas loss of its signaling promotes DNA misrepair that could stimulate immune response. Methods We analyzed transcriptomic data from IMvigor210, The Cancer Genome… Continue reading Identification of a conserved subset of cold tumors responsive to immune checkpoint blockade
Enhancing immunotherapy with tumour-responsive nanomaterials
Abstract The targeted delivery of immunotherapies to tumours using tumour-responsive nanomaterials is a promising area of cancer research with the potential to address the limitations of systemic administration such as on-target off-tumour toxicities and a lack of activity owing to the immunosuppressive tumour microenvironment (TME). Attempts to address these challenges include the design and functionalization… Continue reading Enhancing immunotherapy with tumour-responsive nanomaterials